NAMI has recently started endorsing the Partnership
for Prescription Assistance , a new program that seeks to boost
enrollment in existing Patient Assistance Programs by helping consumers
identify and apply for programs for which they may be eligible. This
may be a good place to start if you are unfamiliar with Assistance
Programs that might work for you - however, we don't yet know how
successful the Partnership is at enrolling people in good programs,
or how much they may charge for their service. If anyone has experiences
to share about the Partnership for Prescription Assistance (good or
bad), please email the administration at: szwebmaster@.
Visit their website ( http:// ) or call 1-888-477-2669 if you are interested.
Free information sites about PAPs - include databases searchable by state, medication, or company name
It should not be used concomitantly with medications known to prolong the QTc interval (. 5-HT3 antagonists , tricyclic antidepressants , citalopram , etc.) as this may lead to an increased risk of QTc interval prolongation.   Neither should it be given concurrently with lithium (medication) as it may increase the risk of lithium toxicity and neuroleptic malignant syndrome .    It should not be given concurrently with other antipsychotics due to the potential for this to increase the risk of side effects, especially neurological side effects such as neuroleptic malignant syndrome .    It should be avoided in patients on CNS depressants such as opioids, alcohol and barbiturates.